Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

THURSDAY, April 17, 2025 (HealthDay News) — A panel of federal health experts on Wednesday recommended expanded vaccine ...

A CDC committee has voted to expand its respiratory syncytial virus vaccine recommendation to include all people aged 50 to ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

A federal panel of medical experts on Wednesday recommended an expansion of respiratory syncytial virus (RSV) vaccinations ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

One less infant, under the age of six months, was hospitalised each day following the release of the Respiratory Syncytial ...

Australians are preparing for significant numbers of respiratory infections this winter, as cases of influenza, RSV, and ...